Cargando…

Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study

BACKGROUND/PURPOSE: One of the most common complications of the peritoneal dialysis (PD) is the infection of the exit site of the peritoneal catheter. The aim of the present study was to evaluate the efficacy of the subcutaneous gentamicin injection around the cuff as a part of routine treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dizdar, Oguzhan Sıtkı, Ozer, Ozerhan, Erdem, Selahattin, Gunal, Ali Ihsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530059/
https://www.ncbi.nlm.nih.gov/pubmed/28790835
http://dx.doi.org/10.2147/TCRM.S140894
_version_ 1783253211743780864
author Dizdar, Oguzhan Sıtkı
Ozer, Ozerhan
Erdem, Selahattin
Gunal, Ali Ihsan
author_facet Dizdar, Oguzhan Sıtkı
Ozer, Ozerhan
Erdem, Selahattin
Gunal, Ali Ihsan
author_sort Dizdar, Oguzhan Sıtkı
collection PubMed
description BACKGROUND/PURPOSE: One of the most common complications of the peritoneal dialysis (PD) is the infection of the exit site of the peritoneal catheter. The aim of the present study was to evaluate the efficacy of the subcutaneous gentamicin injection around the cuff as a part of routine treatment of the resistant exit site infection (ESI). METHODS: If the exit site remains infected after a 2-week systemic antibiotics treatment, it is defined as resistant ESI. In these cases, systemic antibiotics were discontinued and a subcutaneous 40-mg gentamicin injection was administered around the external cuff of the PD catheter every 3 days. A total of three or four injections were given to each patient. RESULTS: A subcutaneous gentamicin injection was administered around the cuff in thirteen patients for the treatment of resistant ESI over a 2-year period. The median follow-up time in cured patients was 12 months. Eleven of the thirteen patients had been apparently cured of their resistant ESI, with no recurrence. None of the patients had a gentamicin-resistant species. Subcutaneous gentamicin-related adverse effect was not observed in any patient. CONCLUSION: Subcutaneous gentamicin injection around the cuff is a well-tolerated and effective strategy for treating resistant ESI. To gain widespread approval of this therapy and reach a consensus about ESI management, additional studies are needed.
format Online
Article
Text
id pubmed-5530059
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55300592017-08-08 Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study Dizdar, Oguzhan Sıtkı Ozer, Ozerhan Erdem, Selahattin Gunal, Ali Ihsan Ther Clin Risk Manag Original Research BACKGROUND/PURPOSE: One of the most common complications of the peritoneal dialysis (PD) is the infection of the exit site of the peritoneal catheter. The aim of the present study was to evaluate the efficacy of the subcutaneous gentamicin injection around the cuff as a part of routine treatment of the resistant exit site infection (ESI). METHODS: If the exit site remains infected after a 2-week systemic antibiotics treatment, it is defined as resistant ESI. In these cases, systemic antibiotics were discontinued and a subcutaneous 40-mg gentamicin injection was administered around the external cuff of the PD catheter every 3 days. A total of three or four injections were given to each patient. RESULTS: A subcutaneous gentamicin injection was administered around the cuff in thirteen patients for the treatment of resistant ESI over a 2-year period. The median follow-up time in cured patients was 12 months. Eleven of the thirteen patients had been apparently cured of their resistant ESI, with no recurrence. None of the patients had a gentamicin-resistant species. Subcutaneous gentamicin-related adverse effect was not observed in any patient. CONCLUSION: Subcutaneous gentamicin injection around the cuff is a well-tolerated and effective strategy for treating resistant ESI. To gain widespread approval of this therapy and reach a consensus about ESI management, additional studies are needed. Dove Medical Press 2017-07-20 /pmc/articles/PMC5530059/ /pubmed/28790835 http://dx.doi.org/10.2147/TCRM.S140894 Text en © 2017 Dizdar et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Dizdar, Oguzhan Sıtkı
Ozer, Ozerhan
Erdem, Selahattin
Gunal, Ali Ihsan
Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
title Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
title_full Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
title_fullStr Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
title_full_unstemmed Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
title_short Subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
title_sort subcutaneous gentamicin injection around the cuff in treatment of resistant exit site infection in peritoneal dialysis patients: a pilot study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530059/
https://www.ncbi.nlm.nih.gov/pubmed/28790835
http://dx.doi.org/10.2147/TCRM.S140894
work_keys_str_mv AT dizdaroguzhansıtkı subcutaneousgentamicininjectionaroundthecuffintreatmentofresistantexitsiteinfectioninperitonealdialysispatientsapilotstudy
AT ozerozerhan subcutaneousgentamicininjectionaroundthecuffintreatmentofresistantexitsiteinfectioninperitonealdialysispatientsapilotstudy
AT erdemselahattin subcutaneousgentamicininjectionaroundthecuffintreatmentofresistantexitsiteinfectioninperitonealdialysispatientsapilotstudy
AT gunalaliihsan subcutaneousgentamicininjectionaroundthecuffintreatmentofresistantexitsiteinfectioninperitonealdialysispatientsapilotstudy